AARDEX Group

AARDEX leading position in the B2B medication adherence market

blog-image
AARDEX still confirms its leading position in the B2B medication adherence market

AARDEX still confirms its leading position in the B2B medication adherence market, closing steadily more new deals with Pharma Companies, Biotech’s, Excellence Centers and Universities, over 30 countries in 2018.

Share This Post

You may also like...

Breaking News

Is Neglecting Medication Adherence in Neurology Drug Trials Putting Patients at Risk?

The list of Neurological conditions is considerable, with epilepsy, Alzheimer’s disease, dementia, stroke, migraine, multiple sclerosis, Parkinson’s disease, neuro infections, and brain tumors, all attributed to this category of disease. Hundreds of millions of people worldwide are affected by neurological

Bias in clinical Research
Breaking News

Unmasking Bias in Clinical Research: A Historical Perspective

It’s an uncomfortable truth that decision-making is a murky business. While we would all like to think that our actions and the choices underpinning them are rooted in logic, integrity, and reason, the truth is not entirely clear-cut. In reality,